English | 简体中文 | 繁體中文 | 한국어
Active Biotech: New data from the Phase 2 LEGATO-HD study will be presented at HSG 2018


New data from the Phase 2 LEGATO-HD study of laquinimod in Huntington's disease will be presented at the scientific conference HSG 2018  

Lund Sweden, November 8, 2018 - Active Biotech (NASDAQ STOCKHOLM: ACTI) announces that new data from the Phase 2 LEGATO-HD study of laquinimod in Huntington's disease will be presented by Global Coordinating Principal Investigator, Dr Ralf Reilmann at the annual Huntington Study Group conference, HSG 2018, in Houston, Texas November 8-10. The results will be presented at an oral session on November 9 and as a poster titled "LEGATO-HD Study: A phase 2 study assessing the efficacy and safety of laquinimod as a treatment for Huntington disease". In addition to previously presented data on primary and secondary endpoints and safety profile, results for exploratory endpoints will be presented. Data for Q-Motor, a sensitive, standardized rate-independent and unbiased measure, revealed nominal improvement on motor coordination in patients treated with laquinimod. These data together with the strong treatment effect on brain volume loss propose a central effect of laquinimod in the LEGATO-HD study.  Additional analysis of the study is ongoing and further results will be presented at upcoming scientific meetings.

The poster will be available on Active Biotech's website (www.activebiotech.com) in connection with the presentation.


LEGATO-HD is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase 2 study of laquinimod as a potential treatment in patients with HD. The study was designed to evaluate three doses arms (0.5mg, 1.0mg, and 1.5mg daily) versus placebo. The highest dose of 1.5 mg was discontinued in January 2016 as a precautionary measure after cardiovascular safety problems were observed in multiple sclerosis studies with laquinimod of 1.2 mg and 1.5 mg respectively. No similar issues were identified in the LEGATO-HD study.

The primary endpoint evaluating the change from baseline at month 12 in the UHDRS-TMS for the 1.0 mg dose as compared with placebo was not achieved. The secondary endpoint, percent change in brain atrophy (caudate volume) from baseline at 12 months in the 1.0 mg dose as compared to placebo, was met. The safety profile in the study was similar to that expected in the patient population. 

Exploratory outcome includes change of Unified Huntington's Disease Rating Scale - Total Motor Score (UHDRS-TMS) and percentage change in brain atrophy for the 0.5 mg dose, as well as changes in measured motor function (Q-motor), cognitive function, functional capacity and brain volumes for the 1.0 and 0.5 mg doses individually. The safety measures included adverse event reporting, clinical laboratory tests, vital signs, electrocardiograms, physical examinations and suicidality.

The study was conducted by Teva in collaboration with the Huntington Study Group and European Huntington's Disease Network. The study is registered as NCT02215616 on clinicaltrials.gov and its EudraCT number is 2014-000418-75.

Lund November 8, 2018
Active Biotech AB (publ)

For further information, please contact:
Helén Tuvesson, CEO
Tel +46 46 19 21 56Email: [email protected]

Hans Kolam, CFO
Tel +46 46 19 20 44
Email: [email protected]

Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an orally administered small molecule with unique immunomodulatory properties in development for neurodegenerative diseases. ANYARA, an immunotherapy, in development for cancer indications in partnership with NeoTX Therapeutics Ltd. Furthermore, commercial activities are conducted for the tasquinimod, paquinimod and SILC projects. Please visit http://www.activebiotech.com/en for more information.

Active Biotech AB
(org.nr 556223-9227)
Box 724, 220 07 Lund
Tfn +46 46 19 20 00

The information was submitted for publication at 13.00 p.m. CET on November 8, 2018.

This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Globenewswire

Copyright © Thomson Reuters 2018. All rights reserved.
Press Releases
Alcon files initial Form 20-F registration statement with SEC for proposed spinoff; plans investor days in New York and London  
Nov 13, 2018 22:28 ET
Merger between Eckert & Ziegler BEBIG SA (BEBIG) and Eckert & Ziegler Strahlen - und Medizintechnik AG (EZAG) - Announcement of the filing of the Joint Terms of Merger  
Nov 13, 2018 21:35 ET
Lubrizol to Showcase New Coating Technologies at IDEA19  
Nov 13, 2018 19:29 ET
Avenir LNG Limited - Private Placement Successfully Completed  
Nov 13, 2018 17:58 ET
Inventiva: 2018 third quarter financial update  
Nov 13, 2018 17:45 ET
Stolt-Nielsen Limited: Avenir LNG Limited Private Placement Successfully Completed  
Nov 13, 2018 17:17 ET
Lubrizol Presents Flexible, Soft and High-Performing Estane® 3DP TPU at Formnext 2018  
Nov 9, 2018 21:59 ET
Lubrizol Collaboration Produces Innovative Fashion-Functional Multi-Tech Commuter Jacket  
Nov 8, 2018 23:29 ET
Ana G. Rodriguez Named Lubrizol Corporate Vice President and Chief Human Resources Officer  
Nov 8, 2018 00:59 ET
Eastman Announces Expiration and Results of Offer to Purchase 5.500% Notes Due 2019  
Nov 6, 2018 22:59 ET
More News >>
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: